GCV Asia Congress 2018
Skip Content

US and Canada

19 December 2017

Aptinyx processes $70m series B

Northwestern University and Osage University Partners both returned to back a $70m series B for Aptinyx, having previously contributed to a $65m series A round in May 2016.

Author: Thierry Heles, editor

Aptinyx, a US-based biopharmaceutical spinout of central nervous system life sciences firm Naurex, closed a $70m series B round yesterday that included Northwestern University and spinout-focused investment firm Osage University Partners (OUP).

The round was led by Bain Capital Life Sciences, while Adage Capital, Agent Capital, HBM Healthcare Investments, Partner Fund Management and Rock Springs Capital also participated. The round further featured Nan Fung Life Sciences, a subsidiary of property development group Nan Fung.

New Leaf Venture Partners, Frazier Healthcare Partners, Longitude Capital, Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital and Beecken Petty O'Keefe & Company also took part.

Founded in 2015, Aptinyx is the result of pharmaceutical firm Allergan acquiring Northwestern University spinout Naurex in a $560m deal. Allergan added Naurex’s anti-depression drug candidates to its portfolio and spun out the discovery platform and preclinical pipeline to Aptinyx.

Aptinyx is working on treatments for brain and nervous system disorders. The company’s drug candidates aim to strengthen the neural cell communication network, boosting synaptic plasticity, which facilitates the creation and storage of memories.

The company has multiple drug candidates, NYX-2925 and NYX-783, in clinical development and hopes to add a third candidate in 2018.

NYX-2925 is undergoing a phase 2 trial for neuropathic pain associated with diabetic peripheral neuropathy and an exploratory study for fibromyalgia. The US regulator Food and Drug Administration (FDA) has granted fast track development for the first indication.

NYX-783 is currently in a phase 1 trial for the treatment of post-traumatic stress disorder. The FDA has also granted fast track designation for this.

The series B funding will drive continued development of Aptinyx’s pipeline. Adam Koppel, managing director at Bain Capital Life Sciences, has joined the board of directors.

Aptinyx previously raised $65m in a series A round in May 2016 led by New Leaf Venture Partners with contributions from Northwestern University, OUP, Adams Street Partners, LVP, PathoCapital, Goudy Park Capital and Beecken Petty O’Keefe & Company.

Northwestern University, Adams Street, LVP, PathoCapital, Goudy Park Capital and Beecken Petty O’Keefe & Company previously supplied an undisclosed amount in seed funding in 2015.

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed